Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1416) 1416
Publication (107) 107
Newsletter (38) 38
Book Review (15) 15
Magazine Article (5) 5
Book Chapter (4) 4
Newspaper Article (2) 2
Paper (2) 2
Data Set (1) 1
Dissertation (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
fenofibrate (905) 905
male (719) 719
humans (688) 688
index medicus (652) 652
animals (471) 471
fenofibrate - administration & dosage (439) 439
female (419) 419
pharmacology & pharmacy (415) 415
middle aged (352) 352
fenofibrate - therapeutic use (335) 335
fenofibrate - pharmacology (307) 307
hypolipidemic agents - administration & dosage (294) 294
hypolipidemic agents - therapeutic use (259) 259
adult (256) 256
rats (251) 251
mice (207) 207
aged (197) 197
cholesterol (195) 195
drug therapy, combination (190) 190
hypolipidemic agents - pharmacology (183) 183
triglycerides - blood (166) 166
lipids (161) 161
research (140) 140
dosage and administration (135) 135
risk factors (131) 131
fenofibrate - adverse effects (130) 130
hyperlipidemias - drug therapy (125) 125
diabetes (124) 124
treatment outcome (123) 123
hypolipidemic agents - adverse effects (119) 119
dyslipidemia (117) 117
lipids - blood (117) 117
fenofibrate - pharmacokinetics (116) 116
drug therapy (115) 115
endocrinology & metabolism (115) 115
solubility (115) 115
metabolism (114) 114
triglycerides (114) 114
dyslipidemias - drug therapy (112) 112
statins (109) 109
cardiac & cardiovascular systems (104) 104
ppar-alpha (101) 101
fibric acids (100) 100
atherosclerosis (98) 98
ppar alpha - agonists (98) 98
cholesterol - blood (97) 97
health aspects (97) 97
biochemistry & molecular biology (95) 95
fenofibrate - chemistry (95) 95
hyperlipidemia (95) 95
coronary-heart-disease (92) 92
dose-response relationship, drug (90) 90
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (90) 90
liver - drug effects (90) 90
rats, sprague-dawley (90) 90
rats, wistar (90) 90
atorvastatin (87) 87
cholesterol, ldl - blood (87) 87
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (87) 87
liver - metabolism (86) 86
metabolic syndrome (85) 85
administration, oral (84) 84
analysis (84) 84
cholesterol, hdl - blood (84) 84
expression (84) 84
liver (84) 84
therapy (84) 84
drugs (83) 83
fenofibrate - analogs & derivatives (83) 83
simvastatin (83) 83
oxidative stress (82) 82
bioavailability (80) 80
cardiovascular-disease (80) 80
inflammation (80) 80
rodents (80) 80
care and treatment (79) 79
double-blind method (79) 79
risk (79) 79
hypolipidemic agents - pharmacokinetics (75) 75
ppar alpha - metabolism (75) 75
biological availability (73) 73
insulin resistance (73) 73
type 2 diabetes (71) 71
dissolution (70) 70
drug delivery systems (69) 69
medicine, general & internal (69) 69
diet (68) 68
disease models, animal (67) 67
gemfibrozil (67) 67
article (66) 66
medicine (66) 66
particle size (65) 65
cardiovascular disease (63) 63
pharmacokinetics (63) 63
diabetes mellitus, type 2 - drug therapy (62) 62
disease (62) 62
medicine, research & experimental (62) 62
physiological aspects (61) 61
chemistry, medicinal (60) 60
mice, inbred c57bl (59) 59
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1379) 1379
Spanish (14) 14
Russian (13) 13
French (11) 11
Japanese (11) 11
Korean (7) 7
Czech (6) 6
Polish (6) 6
German (5) 5
Chinese (4) 4
Hungarian (4) 4
Croatian (1) 1
Portuguese (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience
by Zapletalova, D and André, N and Deak, L and Kyr, M and Bajciova, V and Mudry, P and Dubska, L and Demlova, R and Pavelka, Z and Zitterbart, K and Skotakova, J and Husek, K and Martincekova, A and Mazanek, P and Kepak, T and Doubek, M and Kutnikova, L and Valik, D and Sterba, J
Oncology, ISSN 0030-2414, 05/2012, Volume 82, Issue 5, pp. 249 - 260
Background: The outcome of children with refractory/relapsed malignancies remains poor and novel therapies are urgently required. One of the promising... 
Clinical Study | Tumor angiogenesis | Solid tumor | Children | Metronomic chemotherapy | Relapsed pediatric solid tumor | ANGIOGENESIS | CYCLOPHOSPHAMIDE | TUMOR | NEUROBLASTOMA | CANCER | TRIAL | ONCOLOGY | RECURRENT | RHABDOMYOSARCOMA | MEDULLOBLASTOMA | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Administration, Metronomic | Humans | Child, Preschool | Infant | Isotretinoin - administration & dosage | Male | Feasibility Studies | Young Adult | Angiogenesis Inhibitors - administration & dosage | Dacarbazine - analogs & derivatives | Adult | Female | Registries | Vitamin D - administration & dosage | Child | Dacarbazine - administration & dosage | Europe | Fenofibrate - administration & dosage | Etoposide - administration & dosage | Celecoxib | Neoplasms - drug therapy | Pyrazoles - administration & dosage | Adolescent | Sulfonamides - administration & dosage | Chemotherapy | Children & youth | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Gemfibrozil and fenofibrate, food and drug administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α: Implications for late infantile batten disease therapy
by Ghosh, Arunava and Corbett, Grant T and Gonzalez, Frank J and Pahan, Kalipada
Journal of Biological Chemistry, ISSN 0021-9258, 11/2012, Volume 287, Issue 46, pp. 38922 - 38935
The classical late infantile neuronal ceroid lipofuscinosis (LINCLs) is an autosomal recessive disease, where the defective gene is Cln2, encoding... 
HUMAN ASTROCYTES | MESSENGER-RNAS | ADOPTIVE TRANSFER | BIOCHEMISTRY & MOLECULAR BIOLOGY | MOUSE MODEL | GENE-EXPRESSION | RETINOID-X-RECEPTOR | DENSITY-LIPOPROTEIN-CHOLESTEROL | KAPPA-B | LYSOSOMAL STORAGE DISORDERS | NEURONAL CEROID-LIPOFUSCINOSIS | Neuronal Ceroid-Lipofuscinoses - drug therapy | Up-Regulation | Retinoid X Receptor alpha - metabolism | Serine Proteases - biosynthesis | Humans | Neuronal Ceroid-Lipofuscinoses - metabolism | Gemfibrozil - pharmacology | Hypolipidemic Agents - pharmacology | Brain - drug effects | Brain - metabolism | Fenofibrate - pharmacology | Animals | Lysosomes - metabolism | Gene Expression Regulation, Developmental | Mice | Neurons - metabolism | PPAR alpha - metabolism | Aminopeptidases - biosynthesis | Dipeptidyl-Peptidases and Tripeptidyl-Peptidases - biosynthesis | Astrocytes - metabolism | Gene Regulation | Lysosomes | Enzymology | Peroxisome Proliferator-activated Receptor (PPAR) | Astrocytes | Neurons
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Design of Lipid-Based Formulations for Oral Administration of Poorly Water-Soluble Drugs: Precipitation of Drug after Dispersion of Formulations in Aqueous Solution
by Mohsin, Kazi and Long, Michelle A and Pouton, Colin W
Journal of Pharmaceutical Sciences, ISSN 0022-3549, 10/2009, Volume 98, Issue 10, pp. 3582 - 3595
This study was designed to investigate the precipitation of a lipophilic drug following dispersion of lipid formulations in water. The model drug fenofibrate... 
SEDDS | lipid formulation classification system | oral drug delivery | SMEDDS | self-emulsifying systems | self-emulsifying drug delivery systems | drug precipitation | self‐emulsifying systems | self‐emulsifying drug delivery systems | Drug precipitation | Lipid formulation classification system | Self-emulsifying systems | Oral drug delivery | Selfemulsifying drug delivery systems | CHEMISTRY, MEDICINAL | DELIVERY-SYSTEMS | GASTROINTESTINAL-TRACT | LIPOPHILIC DRUGS | CHEMISTRY, MULTIDISCIPLINARY | BIOAVAILABILITY | SOLUBILITY | DIGESTION | LIPOLYSIS | PHARMACOKINETICS | PHARMACOLOGY & PHARMACY | ABSORPTION | CYCLOSPORINE | Water | Solvents | Excipients | Emulsions | Solubility | Fenofibrate - administration & dosage | Electric Conductivity | Chromatography, High Pressure Liquid | Fenofibrate - chemistry | Chemistry, Pharmaceutical | Lipids - chemistry | Solutions | Hypolipidemic Agents - administration & dosage | Pharmaceutical Preparations - chemistry | Hypolipidemic Agents - chemistry
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability
by He, Wei and Yang, Ke and Fan, Lifang and Lv, Yaqi and Jin, Zhu and Zhu, Shumin and Qin, Chao and Wang, Yiao and Yin, Lifang
International Journal of Pharmaceutics, ISSN 0378-5173, 11/2015, Volume 495, Issue 1, pp. 9 - 18
Oral drug delivery is the most preferred route for patients; however, the low solubility of drugs and the resultant poor absorption compromise the benefits of... 
Absorption mechanism | Nanoemulsions | Insoluble drug | Pharmacokinetics | Globular protein | Solidification | MECHANISM | VIVO | NANOCARRIERS | MICELLES | FORMULATION | DIRECT CYTOSOLIC DELIVERY | TRANSPORT | NANOSUSPENSIONS | PHARMACOLOGY & PHARMACY | ABSORPTION | Nanoparticles - chemistry | Soybean Proteins - pharmacokinetics | Emulsions - adverse effects | Humans | Bile Acids and Salts - chemistry | Drug Carriers - administration & dosage | Biological Availability | Fenofibrate - chemistry | Soybean Proteins - chemistry | Drug Carriers - chemistry | Intestinal Absorption | Tissue Distribution | Emulsions - administration & dosage | Bile Acids and Salts - administration & dosage | Protein Denaturation | Water - chemistry | Bile Acids and Salts - pharmacokinetics | Caco-2 Cells | Cell Survival - drug effects | Soybean Proteins - administration & dosage | Administration, Oral | Emulsions - chemistry | Nanoparticles - ultrastructure | Solubility | Fenofibrate - administration & dosage | Rats | Chemistry, Pharmaceutical | Fenofibrate - blood | Particle Size | Fenofibrate - pharmacokinetics | Animals | Suspensions - pharmacokinetics | Drug Carriers - pharmacokinetics | Nanoparticles - administration & dosage | Emulsions - pharmacokinetics | Drugs | Drug delivery systems | Analysis | Gastrointestinal system | Vehicles
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics
by Leonard, CE and Bilker, WB and Brensinger, CM and Han, X and Flory, JH and Flockhart, DA and Gagne, JJ and Cardillo, S and Hennessy, S
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 05/2016, Volume 99, Issue 5, pp. 538 - 547
Drug–drug interactions causing severe hypoglycemia due to antidiabetic drugs is a major clinical and public health problem. We assessed whether sulfonylurea... 
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hypoglycemia - epidemiology | Glipizide - administration & dosage | Humans | Middle Aged | Glipizide - adverse effects | Male | Fenofibrate - adverse effects | Incidence | Drug Interactions | Hypoglycemic Agents - administration & dosage | Female | Retrospective Studies | Sulfonylurea Compounds - administration & dosage | Glyburide - administration & dosage | Hypoglycemia - chemically induced | Glyburide - adverse effects | Severity of Illness Index | Hypolipidemic Agents - adverse effects | Fenofibrate - administration & dosage | Sulfonylurea Compounds - adverse effects | Algorithms | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hypolipidemic Agents - administration & dosage | Aged | Hypoglycemic Agents - adverse effects | Cohort Studies | GEMFIBROZIL | GLYCEMIC CONTROL | CHEMISTRY, MEDICINAL | PROPENSITY SCORE | GLUCOSE-METABOLISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | PRAVASTATIN | TYPE-2 DIABETES-MELLITUS | INSULIN SENSITIVITY | GLYBURIDE | CORONARY-ARTERY-DISEASE | DRUG-INDUCED HYPOGLYCEMIA | Care and treatment | Dosage and administration | Management | Hypoglycemia | Hypoglycemic sulfonylureas | Sulfonylurea compounds | Risk factors | Public health | drug interactions | fibric acids | sulfonylurea compounds | hypoglycemia | cohort studies | hydroxymethylglutaryl-CoA reductase inhibitors | Medicaid | pharmacoepidemiology | propensity score
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Renal failure related to fibrates administration (n=46)
by Casas, CRC and Diaz, BM and Tabares, LG and Larrambe, NG and Gonzalez, LC and Merino, MLG and Varela, JC
NEFROLOGIA, ISSN 0211-6995, 03/2017, Volume 37, Issue 2, pp. 216 - 217
SERUM CREATININE | UROLOGY & NEPHROLOGY | FENOFIBRATE THERAPY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Circulating Proprotein Convertase Subtilisin Kexin Type 9 Has a Diurnal Rhythm Synchronous With Cholesterol Synthesis and Is Reduced by Fasting in Humans
by Persson, Lena and Cao, Guoqing and Ståhle, Lars and Sjöberg, Beatrice G and Troutt, Jason S and Konrad, Robert J and Gälman, Cecilia and Wallén, Håkan and Eriksson, Mats and Hafström, Ingiäld and Lind, Suzanne and Dahlin, Maria and Åmark, Per and Angelin, Bo and Rudling, Mats
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 12/2010, Volume 30, Issue 12, pp. 2666 - 2672
OBJECTIVE—To gain insight into the function of proprotein convertase subtilisin kexin type 9 (PCSK9) in humans by establishing whether circulating levels are... 
cholesterol synthesis | circulating PCSK9 | diurnal rhythm | growth hormone | LDL cholesterol | cholesterol-lowering drugs | lipoproteins | PLASMA PCSK9 | DENSITY-LIPOPROTEIN RECEPTORS | BILE-ACID SYNTHESIS | FENOFIBRATE TREATMENT | TARGET GENES | GROWTH-HORMONE | LIVER-REGENERATION | SERUM-LEVELS | PERIPHERAL VASCULAR DISEASE | MICE | HEMATOLOGY | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Cholesterol - blood | Humans | Male | Sweden | Liver - drug effects | Fasting - blood | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Cholesterol, LDL - blood | Female | Human Growth Hormone - administration & dosage | Proprotein Convertases | Diet, Ketogenic | Down-Regulation | Liver - metabolism | Receptors, LDL - metabolism | Circadian Rhythm | Energy Intake | Cross-Over Studies | Atorvastatin Calcium | Anticholesteremic Agents - administration & dosage | Serine Endopeptidases - blood | Cholesterol - biosynthesis | Cholestyramine Resin - administration & dosage | Proprotein Convertase 9
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Effect of Switch to the Highest Dose of Rosuvastatin Versus Add‐on‐Statin Fenofibrate Versus Add‐on‐Statin Nicotinic Acid/Laropiprant on Oxidative Stress Markers in Patients with Mixed Dyslipidemia
by Kei, Anastazia and Tellis, Constantinos and Liberopoulos, Evangelos and Tselepis, Alexandros and Elisaf, Moses
Cardiovascular Therapeutics, ISSN 1755-5914, 08/2014, Volume 32, Issue 4, pp. 139 - 146
Summary Introduction Oxidative stress plays an important role in atherosclerosis. Both F2‐isoprostane (8‐iso‐PGF2a) and oxidized low‐density lipoprotein... 
nicotinic acid/laropiprant | fenofibrate | oxidized LDL | F2‐Isoprostanes | rosuvastatin | oxidative stress | mixed dyslipidemia | Fenofibrate | Oxidative stress | Nicotinic acid/laropiprant | Oxidized LDL | F2-Isoprostanes | Rosuvastatin | Mixed dyslipidemia | CARDIAC & CARDIOVASCULAR SYSTEMS | ACID | ATHEROSCLEROSIS | RISK | APOLIPOPROTEINS | COMBINATION | HIGH-DENSITY-LIPOPROTEIN | THERAPY | PHARMACOLOGY & PHARMACY | CIRCULATING OXIDIZED LDL | AUTOANTIBODY | HYPOLIPIDEMIC TREATMENT | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Dinoprost - blood | Prospective Studies | Humans | Middle Aged | Apolipoprotein B-100 - blood | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Fenofibrate - adverse effects | Greece | Niacin - administration & dosage | Dyslipidemias - blood | Time Factors | Pyrroles - administration & dosage | Heptanoic Acids - administration & dosage | Niacin - adverse effects | Female | Dinoprost - analogs & derivatives | Uric Acid - blood | Drug Therapy, Combination | Dyslipidemias - diagnosis | Hypolipidemic Agents - adverse effects | Dyslipidemias - drug therapy | Pyrimidines - administration & dosage | Simvastatin - administration & dosage | Fenofibrate - administration & dosage | Rosuvastatin Calcium | Treatment Outcome | Biomarkers - blood | Atorvastatin Calcium | Bilirubin - blood | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Indoles - adverse effects | Hypolipidemic Agents - administration & dosage | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Oxidative Stress - drug effects | Lipoproteins, LDL - blood | Sulfonamides - administration & dosage | Care and treatment | Low density lipoproteins | Analysis | Simvastatin | Atherosclerosis | Fibric acids | Cardiovascular agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Safety assessment of niacin in the US Food and Drug Administration's mini‐sentinel system
by Gagne, Joshua J and Houstoun, Monika and Reichman, Marsha E and Hampp, Christian and Marshall, James H and Toh, Sengwee
Pharmacoepidemiology and Drug Safety, ISSN 1053-8569, 01/2018, Volume 27, Issue 1, pp. 30 - 37
Purpose The Heart Protection Study 2—Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2‐THRIVE) trial found higher incidence rates of adverse... 
niacin | sentinel | bleeding | safety | pharmacoepidemiology | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | THERAPY | EXTENDED-RELEASE NIACIN/LAROPIPRANT | MODELS | PHARMACOLOGY & PHARMACY | LAROPIPRANT | United States - epidemiology | Hyperlipidemias - blood | United States Food and Drug Administration - statistics & numerical data | Follow-Up Studies | Humans | Middle Aged | Male | Gastrointestinal Hemorrhage - epidemiology | Delayed-Action Preparations - administration & dosage | Fenofibrate - adverse effects | Incidence | Niacin - administration & dosage | Young Adult | Aged, 80 and over | Niacin - adverse effects | Adult | Female | Adverse Drug Reaction Reporting Systems - statistics & numerical data | Hypolipidemic Agents - adverse effects | Hyperlipidemias - drug therapy | Fenofibrate - administration & dosage | Gastrointestinal Hemorrhage - chemically induced | Delayed-Action Preparations - adverse effects | Intracranial Hemorrhages - chemically induced | Hypolipidemic Agents - administration & dosage | Cholesterol, HDL - blood | Intracranial Hemorrhages - epidemiology | Aged | Niacin | Analysis | Safety and security measures | Sensitivity analysis | Initiators | Sentinel system | Data processing | Hazards | Hemorrhage | Bleeding | Confidence intervals | Fenofibrate | Statistical models | Vitamin B | Lipoproteins (high density)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Comparisons of pharmacokinetics and NO‐releasing of nitrofibriate and fenofibrate after oral administration in rats
by Yang, Yujie and Cheng, Qiang and Liu, Xiumei and Liu, Zejuan and Li, Tingting and Jiang, Xuehua and Wang, Ling
Biomedical Chromatography, ISSN 0269-3879, 12/2016, Volume 30, Issue 12, pp. 2003 - 2008
Nitrofibriate, a new compound of hypolipidemic, is modified based on fenofibrate. Both of them are used for prevention and treatment of cardiovascular... 
pharmacokinetics | nitrofibriate | RP‐HPLC | RP-HPLC | CHEMISTRY, ANALYTICAL | REDUCTION | PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIOCHEMICAL RESEARCH METHODS | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | Nitric Oxide - blood | Nitro Compounds - pharmacokinetics | Limit of Detection | Reproducibility of Results | Administration, Oral | Nitro Compounds - blood | Fenofibrate - administration & dosage | Fenofibrate - analogs & derivatives | Rats | Male | Rats, Sprague-Dawley | Fenofibrate - blood | Nitro Compounds - administration & dosage | Fenofibrate - pharmacokinetics | Animals | Female | Metabolites | Nitric oxide | High performance liquid chromatography
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
by Jones, Peter H and Davidson, Michael H
The American Journal of Cardiology, ISSN 0002-9149, 2005, Volume 95, Issue 1, pp. 120 - 122
There is an increasing trend among physicians to use 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in combination with other... 
Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Hypolipidemic Agents - adverse effects | Rhabdomyolysis - epidemiology | Adverse Drug Reaction Reporting Systems | United States | Humans | Fenofibrate - administration & dosage | Gemfibrozil - adverse effects | Fenofibrate - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hypolipidemic Agents - administration & dosage | Rhabdomyolysis - chemically induced | Retrospective Studies | Drug Therapy, Combination | Gemfibrozil - administration & dosage | United States Food and Drug Administration | Medical colleges | Coenzymes | Thiols | Pharmacy | Anticholesteremic agents | Rhabdomyolysis | Cardiovascular agents | Antilipemic agents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text A phase II trial of a multi‐agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer
by Robison, Nathan J and Campigotto, Federico and Chi, Susan N and Manley, Peter E and Turner, Christopher D and Zimmerman, Mary Ann and Chordas, Christine A and Werger, Annette M and Allen, Jeffrey C and Goldman, Stewart and Rubin, Joshua B and Isakoff, Michael S and Pan, Wilbur J and Khatib, Ziad A and Comito, Melanie A and Bendel, Anne E and Pietrantonio, Jay B and Kondrat, Laura and Hubbs, Shannon M and Neuberg, Donna S and Kieran, Mark W
Pediatric Blood & Cancer, ISSN 1545-5009, 04/2014, Volume 61, Issue 4, pp. 636 - 642
Background Preclinical models show that an antiangiogenic regimen at low‐dose daily (metronomic) dosing may be effective against chemotherapy‐resistant tumors.... 
drug resistance | pediatric oncology | phase II clinical trials | angiogenesis | Pediatric oncology | Angiogenesis | Drug resistance | Phase II clinical trials | THROMBOSPONDIN-1 | VINBLASTINE | TUMOR ANGIOGENESIS | CHEMOTHERAPY | ETOPOSIDE | THERAPY | INHIBITION | ONCOLOGY | LOW-GRADE GLIOMA | GROWTH | PEDIATRICS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Child, Preschool | Neoplasm Recurrence, Local - drug therapy | Infant | Male | Neoplasm Recurrence, Local - pathology | Young Adult | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Child | Fenofibrate - administration & dosage | Etoposide - administration & dosage | Survival Rate | Celecoxib | Thalidomide - administration & dosage | Neoplasms - drug therapy | Pyrazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Adolescent | Neoplasm Staging | Neoplasms - pathology | Sulfonamides - administration & dosage | Antimitotic agents | Chemotherapy | Relapse | Gliomas | Analysis | Leukemia | Clinical trials | Product development | Antineoplastic agents | Diseases | Cancer | Pediatrics | Drug dosages | Cancer therapies | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Safety and Efficacy of Long-Term Co-Administration of Fenofibrate and Ezetimibe in Patients With Mixed Hyperlipidemia
by McKenney, James M and Farnier, Michel and Lo, Kwok-Wing and Bays, Harold E and Perevozkaya, Inna and Carlson, Gary and Davies, Michael J and Mitchel, Yale B and Gumbiner, Barry
Journal of the American College of Cardiology, ISSN 0735-1097, 04/2006, Volume 47, Issue 8, pp. 1584 - 1587
Safety and Efficacy of Long-Term Co-Administration of Fenofibrate and Ezetimibe in Patients With Mixed Hyperlipidemia James M. McKenney, Michel Farnier,... 
CARDIAC & CARDIOVASCULAR SYSTEMS | CHOLESTEROL ABSORPTION INHIBITOR | PRIMARY HYPERCHOLESTEROLEMIA | Humans | Middle Aged | Ezetimibe | Male | Fenofibrate - therapeutic use | Fenofibrate - adverse effects | Lipids - blood | Adult | Female | Drug Therapy, Combination | Hypolipidemic Agents - adverse effects | Double-Blind Method | Drug Administration Schedule | Azetidines - adverse effects | Fenofibrate - administration & dosage | Hyperlipidemia, Familial Combined - blood | Treatment Outcome | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - therapeutic use | Azetidines - administration & dosage | Azetidines - therapeutic use | Anticholesteremic Agents - administration & dosage | Hypolipidemic Agents - administration & dosage | Aged | Hyperlipidemia, Familial Combined - drug therapy | Hypolipidemic Agents - therapeutic use | Care and treatment | Hyperlipidemia | Creatine kinase | Low density lipoproteins | Atherosclerosis | Amino acids | Triglycerides | Cholesterol | Fibric acids | Apolipoproteins | Proteins | Gallbladder diseases | Lipids | Diabetes | Low density lipoprotein
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights